HCAT · Insider Trading
Health Catalyst, Inc Common Stock
Every open-market purchase and sale reported by HCAT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Tami Reller | Director | A | +128,851 | — |
| 2026-09-16 | Simeon Kohl | Chief Executive Officer | MIXED | +2,806,385 | +$105.44K |
| 2026-09-11 | Benjamin Albert | CEO | F | −35,244 | −$59.02K |
| 2026-09-03 | Julie Larson-Green | Director | A | +9,766 | — |
| 2026-09-03 | Benjamin Landry | General Counsel | F | −13,167 | −$22.43K |
| 2026-09-03 | Jason Alger | Chief Financial Officer | F | −17,973 | −$30.62K |
| 2026-09-03 | Benjamin Albert | CEO | F | −321 | −$547 |
| 2026-07-20 | Julie Larson-Green | Director | A | +80,691 | — |
| 2026-07-20 | Justin Spencer | Director | A | +80,691 | — |
| 2026-07-20 | Steven H Nelson | Director | A | +80,691 | — |
| 2026-07-20 | Green Jill Hoggard | Director | A | +80,691 | — |
| 2026-06-15 | Benjamin Albert | CEO | F | −34,485 | −$58.34K |
| 2026-06-03 | Jason Alger | Chief Financial Officer | F | −18,804 | −$25.77K |
| 2026-06-03 | Benjamin Albert | CEO | F | −336 | −$460 |
| 2026-06-03 | Benjamin Landry | General Counsel | F | −13,779 | −$18.88K |
| 2026-06-03 | Linda Llewelyn | Chief People Officer | F | −8,519 | −$11.67K |
| 2026-06-03 | Julie Larson-Green | Director | A | +12,710 | — |
| 2026-05-04 | Steven H Nelson | Director | A | +154,808 | — |
| 2026-05-01 | Benjamin Albert | CEO | MIXED | +814 | −$417 |
| 2026-03-13 | Benjamin Albert | CEO | F | −70,455 | −$130.21K |
| 2026-03-05 | Jason Alger | Chief Financial Officer | F | −26,970 | −$44.77K |
| 2026-03-05 | Julie Larson-Green | Director | A | +8,361 | — |
| 2026-03-05 | Benjamin Albert | CEO | F | −4,966 | −$8.24K |
| 2026-03-05 | Linda Llewelyn | Chief People Officer | F | −13,836 | −$22.97K |
| 2026-03-05 | Benjamin Landry | General Counsel | F | −20,838 | −$34.59K |
| 2026-02-27 | Linda Llewelyn | Chief People Officer | MIXED | +200,224 | −$7.81K |
| 2026-02-27 | Benjamin Landry | General Counsel | MIXED | +299,156 | −$11.04K |
| 2026-02-27 | Jason Alger | Chief Financial Officer | MIXED | +522,200 | −$13.15K |
| 2026-02-27 | Benjamin Albert | CEO | MIXED | +955,529 | −$23.25K |
| 2026-02-19 | Duncan Gallagher | Director | A | +7,562 | — |
| 2025-12-09 | Julie Larson-Green | Director | Sell | −47,997 | −$128.35K |
| 2025-12-09 | Benjamin Landry | General Counsel | Sell | −27,425 | −$72.33K |
| 2025-12-03 | Linda Llewelyn | Chief People Officer | F | −9,762 | −$28.31K |
| 2025-12-03 | Daniel D. Burton | Chief Executive Officer | F | −55,715 | −$161.58K |
| 2025-12-03 | Duncan Gallagher | Director | A | +6,209 | — |
| 2025-12-03 | Kevin Lee Freeman | Chief Commercial Officer | F | −16,401 | −$47.57K |
| 2025-12-03 | Benjamin Landry | General Counsel | F | −14,387 | −$41.73K |
| 2025-12-03 | Julie Larson-Green | Director | A | +5,731 | — |
| 2025-12-03 | Jason Alger | Chief Financial Officer | F | −20,619 | −$59.80K |
| 2025-09-26 | Benjamin Albert | President and COO | A | +467,000 | — |
| 2025-09-09 | Benjamin Landry | General Counsel | Sell | −6,175 | −$20.70K |
| 2025-09-05 | Duncan Gallagher | Director | A | +4,970 | — |
| 2025-09-05 | Julie Larson-Green | Director | A | +4,588 | — |
| 2025-09-04 | Jason Alger | Chief Financial Officer | F | −2,613 | −$8.79K |
| 2025-09-04 | Daniel D. Burton | Chief Executive Officer | F | −8,335 | −$28.03K |
| 2025-09-04 | Daniel LeSueur | Chief Operating Officer | F | −3,663 | −$12.32K |
| 2025-09-04 | Benjamin Landry | General Counsel | F | −3,138 | −$10.55K |
| 2025-09-04 | Linda Llewelyn | Chief People Officer | F | −2,854 | −$9.60K |
| 2025-09-04 | David Coy Ross | Chief Tech & Product Officer | F | −3,360 | −$11.30K |
| 2025-09-04 | Kevin Lee Freeman | Chief Commercial Officer | F | −4,578 | −$15.39K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Simeon Kohl | Chief Executive Officer | 2,856,385 | $4.31M |
| Daniel D. Burton | Chief Executive Officer | 1,393,099 | $2.10M |
| Benjamin Albert | CEO | 1,388,406 | $2.10M |
| Jason Alger | Chief Financial Officer | 704,867 | $1.06M |
| Kevin Lee Freeman | Chief Commercial Officer | 358,686 | $541.62K |
| Benjamin Landry | General Counsel | 351,372 | $530.57K |
| Linda Llewelyn | Chief People Officer | 321,132 | $484.91K |
| Steven H Nelson | Director | 235,499 | $355.60K |
| David Coy Ross | Chief Tech & Product Officer | 204,219 | $308.37K |
| Daniel LeSueur | Chief Operating Officer | 198,367 | $299.53K |
| Julie Larson-Green | Director | 185,101 | $279.50K |
| John A Kane | Director | 170,719 | $257.79K |
| Justin Spencer | Director | 149,263 | $225.39K |
| Green Jill Hoggard | Director | 144,628 | $218.39K |
| Duncan Gallagher | Director | 132,023 | $199.35K |
| Tami Reller | Director | 128,851 | $194.57K |
| S. Dawn Smith | Director | 101,692 | $153.55K |
| Anita Pramoda | Director | 62,503 | $94.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HCAT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.